Condition
Mesothelioma
Estimated Enrollment: 248
Age Group: 18 Years and older (Adult, Senior)
Gender: All
Study Type: Interventional
Study Design Allocation: Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: No masking|Primary Purpose: Treatment
Study ID Numbers: 15743|2012-003650-88
Study First Received: November 9, 2015
Last Updated: February 13, 2017
Estimated Primary Completion Date: November 2017
Primary Outcome Measures:
Progression Free Survival|Overall survival (OS)|Patient-reported outcomes (PROs)|Objective response rate (ORR)|Duration of response (DOR)|Number of participants with treatment emergent adverse events as a measure of safety and tolerability|Number of participants with serious adverse events as a measure of safety and tolerability|Disease control rate (DCR)|Durable Response Rate (DRR)
Sponsors and Collaborators:
Bayer|ImmunoGen and MorphoSys
Website Link: https://ClinicalTrials.gov/show/NCT02610140
